Elutia (ELUT) EBIT Margin (2019 - 2026)

Elutia (ELUT) posted EBIT Margin of 203.85% for Q1 2026, down 1.63% sequentially from 200.58% in Q4 2025, and up 2580.0% YoY from 7.61% in Q1 2025.

Elutia (ELUT) EBIT Margin (2019 - 2026) Analysis & Trends

Elutia has reported EBIT Margin for 8 years, with the latest figure at 203.85% in Q1 2026.

Quarterly EBIT Margin rose 2580.0% year-over-year to 203.85% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 175.27% (up 2779.0% YoY) and the FY2025 annual result came in at 218.91%, down 662.0% from the prior year.
EBIT Margin retreated to 203.85% in Q1 2026 per ELUT's latest filing, from 200.58% in the prior quarter.
Over five years, EBIT Margin peaked at 60.22% in Q1 2022 and troughed at 264.84% in Q4 2024.
A 5-year average of 155.51% and a median of 144.82% in 2023 frame the typical range for EBIT Margin.
The sharpest annual moves came in 2024 and 2025: EBIT Margin tumbled 13024 bps in 2024, then soared 9382 bps in 2025.
Over 5 years, EBIT Margin stood at 144.63% in 2022, then retreated by 0 bps to 144.82% in 2023, then plunged by 83 bps to 264.84% in 2024, then gained by 24 bps to 200.58% in 2025, then decreased by 2 bps to 203.85% in 2026.
According to Business Quant data, EBIT Margin over the past three periods registered 203.85%, 200.58%, and 156.73% for Q1 2026, Q4 2025, and Q3 2025 respectively.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	EBIT Margin (Qtr)
1	Abbott Laboratories	198.70 Bn	193.10 Bn	7.27 Bn	13.44%
2	Stryker	125.85 Bn	122.37 Bn	4.50 Bn	25.18%
3	Medtronic	118.44 Bn	109.22 Bn	6.41 Bn	19.10%
4	Boston Scientific	72.64 Bn	72.10 Bn	3.85 Bn	21.65%
5	Edwards Lifesciences	51.94 Bn	47.69 Bn	1.35 Bn	29.48%
6	Dexcom	34.48 Bn	32.53 Bn	830.00 Mn	24.33%
7	GE HealthCare Technologies	33.60 Bn	31.49 Bn	2.18 Bn	13.96%
8	Koninklijke Philips	26.30 Bn	22.98 Bn	4.55 Bn	10.30%
9	Steris	23.00 Bn	22.52 Bn	684.20 Mn	19.15%
10	Elutia	39.87 Mn	19.98 Mn	1.45 Mn	-327.85%

Download Data